治疗肺动脉高压新药-Selexipag研究进展  

Advances in research of pulmonary hypertension:Selexipag

作　　者：王艳[1] 张四喜[1] 闫荟羽[1] 周微[1] 

机构地区：[1]吉林大学第一医院药学部,吉林长春130021

出　　处：《中国医院药学杂志》2017年第15期1540-1545,共6页Chinese Journal of Hospital Pharmacy

摘　　要：肺动脉高压是以血管收缩、血管重构、平滑肌细胞增殖和原位血栓形成等为主要特征的肺小动脉异常疾病。Selexipag是一种新型口服前列环素受体激动剂,已被证明可改善Ⅱ期临床试验的血液动力学,并可减少Ⅲ期临床试验中肺动脉高压患者的疾病恶化情况。本文对其作用机制、药动学、药效学、临床试验、不良反应等方面做一综述。Pulmonary arterial hypertension is characterized by abnormalities in the small pulmonary arteries, including in- creased vasoconstriction, vascular remodeling, proliferation of smooth muscle cells, and in situ thrombosis. Selexipag, a novel, oral prostacyclin receptor agonist, has been shown to improve hemodynamics in a phase Ⅱ clinical trial and reduce clinical worsening in a large phase Ⅲ clinical trial involving patients with pulmonary arterial hypertension. In this paper, we describe the action mechanism, pharmacokinetics, pharmacodynamics, clinical studies and adverse events of Selexipag are described.

关 键 词：Selexipag 肺动脉高压 前列环素 

分 类 号：R972.4[医药卫生—药品]